MEIG1 CRISPR Activation Plasmid (h): sc-418750-ACT

MEIG1 (meiosis expressed gene 1) encodes a small, germ cell–enriched protein implicated in spermatogenesis and meiotic progression, with reported roles in regulating post-transcriptional gene expression during male germ cell differentiation. In testis, MEIG1 has been linked to assembly and transport of protein complexes required for spermiogenesis, supporting processes such as manchette-associated cargo trafficking and flagellar development. Dysregulation of MEIG1-associated pathways is relevant to studies of male infertility and defective sperm morphogenesis, and its restricted expression profile makes it useful for dissecting germline-specific regulatory programs. In human systems, MEIG1 serves as a tractable node for probing transcriptional and post-transcriptional networks that coordinate meiosis and sperm cell maturation.

MEIG1 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous MEIG1 expression without altering the underlying DNA sequence.

MEIG1 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the MEIG1 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.

Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the MEIG1 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous MEIG1 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native MEIG1 locus and enabling the study of MEIG1-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of MEIG1 pathway restoration in tumor cells with silenced or reduced MEIG1 expression.

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.